US SB2276

Limits patent holders to asserting only one patent per "Patent Group" in infringement lawsuits against generic drug or biosimilar manufacturers

Defines "Patent Group" as commonly owned patents linked through terminal disclaimers filed to overcome obviousness-type double patenting rejections

Prohibits patent holders from filing additional lawsuits asserting other patents from the same Patent Group against the same defendant

Applies to generic drug applications under Section 505(b)(2) or 505(j) of the Federal Food, Drug, and Cosmetic Act and biosimilar applications under Section 351(k) of the Public Health Service Act

Takes effect for applications submitted on or after the date of enactment